The cooperation includes three tests in the field of intensive care, and four immunoassays on risk prediction in the field of breast cancer, cardiovascular disease, chronic kidney disease, and Alzheimer’s disease. In intensive care, the cooperation is on biomarker-based detection of acute renal injury (AKI), vascular dysfunction and septic shock. Shuwen Biotech is a Sino-American company focused on molecular tests and in-vitro diagnostics; the Chinese affiliation is based near Hangzhou, Zhejiang Province, http://shuwenbiotech.com
China Bio news release, August 14, 2017